Literature DB >> 2681764

Intermittent control of hyperuricemia in the treatment of gout.

P W Bull1, J T Scott.   

Abstract

Fifty patients with gout were randomly allocated to one of 2 groups receiving allopurinol, either continuously or for 2 months every year. Patients with renal functional impairment or tophacous gout were excluded. Duration of treatment ranged from 2-4 years. Acute gouty arthritis occurred to a similar degree in the 2 groups during the first year, but thereafter attacks occurred with diminishing frequency in the continuous group compared with the intermittent group. We concluded that the intermittent administration of allopurinol as given here is less effective in controlling symptoms of gout than continuous therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2681764

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 2.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Why is gout so poorly managed?

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

Review 4.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

5.  Health care utilization in patients with gout.

Authors:  Jasvinder A Singh; A Sarkin; M Shieh; D Khanna; R Terkeltaub; S J Lee; A Kavanaugh; J D Hirsch
Journal:  Semin Arthritis Rheum       Date:  2010-09-09       Impact factor: 5.532

Review 6.  Management of gout in older adults: barriers to optimal control.

Authors:  Karl T Hoskison; Robert L Wortmann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 9.  Risks and benefits of drugs used in the management and prevention of gout.

Authors:  P G Conaghan; R O Day
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

10.  Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice.

Authors:  Jasvinder A Singh; John S Richards; Elizabeth Chang; Karine Toupin-April; Jennifer L Barton
Journal:  Clin Rheumatol       Date:  2020-09-30       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.